Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 294 participants.
Also called NCT07799779
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 294 participants
- Registry
-
NCT07799779
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07799779. Randomized; single masking; primary purpose treatment. Start 2026-11-30 (anticipated); primary completion 2029-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome
- Acronym
- SEsiR-ACS
- Condition
- Acute Coronary Syndromes (ACS)
- Intervention (Drug)
- Inclisiran
- Intervention (Drug)
- Atorvastatin or Rosuvastatin
- Intervention (Drug)
- Ezetimibe
- Lead sponsor
- Seoul National University Bundang Hospital
- Collaborator
- Dotter Co., Ltd.
- Collaborator
- Novartis Korea Ltd.
- Collaborator
- Hanmi Pharmaceutical co., ltd.
Record details
- Record id
cardio:ct-nct07799779- Content hash
8cd0e11dbe63ce9b164ef13ff55d0eb23fe85176e72b17100c59511d6061d650